Sign inJoin waitlistJoin the waitlist

Alfred Chung

Hematology · Ucsf Medical Group Business Services

Credentials: · · ·

History

Stanford University
Until 2020
Stanford University
Until 2017
Northwestern University - Feinberg School of Medicine
2014
University of Michigan - Ann Arbor
2010

Research

Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins
Molecular Pharmacology · 2010 · 60 citations
Graphene as cellular interface: electromechanical coupling with cells
ACS Nano · 2011 · 55 citations
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Blood · 2025 · 51 citations

Thomas Martin
16 papers
Jeffrey Wolf
15 papers
Shagun Arora
14 papers
SW
Sandy Wong
12 papers
NS
Nina Shah
9 papers
Ajai Chari
8 papers
Anupama Kumar
8 papers · 1 as a fellow
Rahul Banerjee
7 papers
Darren Pan
4 papers · 2 as a fellow
Jodi Lipof
4 papers
Peter Sayre
4 papers
Arun Wiita
3 papers

Clinical trials

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 1
Alfred Chung, MD
2025–2029
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
Principal investigator · Withdrawn · Phase 1, Phase 2
Alfred Chung, MD
2024–2028
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Principal investigator · Terminated · Phase 2
Alfred Chung, MD
2022–2023
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Principal investigator · Terminated · Phase 2
University of California, San Francisco
2020–2023